| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Wright Robin is a Director at BRNS. Recent filings cover 3 purchases and 0 sales. Those positions are worth an estimated $128K at current prices.
Our model assigns Wright Robin a below-average insider score of 23/100, based on 3 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -49.2%.
Wright Robin's largest disclosed position is in BRNS as Director, worth about $128K. Net of sales, the recent Form 4 record there shows accumulation of 37,750 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2023 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 13,750 | $2.66 | $36,612.13 | +39.8% | -21.6% | -11.6% | |
| Dec 22, 2021 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 10,000 | $9.97 | $99,700.00 | +40.8% | -41.8% | -73.8% | |
| May 4, 2021 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 14,000 | $17.00 | $238,000.00 | +133.3% | +14.1% | -62.1% |